Aortic stenosis resident survival guide
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]; Rim Halaby, M.D. [3]
Aortic Stenosis Resident Survival Guide Microchapters |
---|
Overview |
Causes |
FIRE |
Diagnosis |
Treatment |
Do's |
Don'ts |
Overview
Aortic stenosis is the progressive narrowing of the diameter of the aortic valve (normal valve area is 3 - 4 cm²). The symptoms are caused by a decrease in the stroke volume which reduces blood flow to peripheral tissues. The most common etiology of aortic stenosis is calcific aortic valve disease. The management of aortic stenosis depends on the stage of the disease which is determined by whether the patient is symptomatic or asymptomatic, the area of the valve, and the hemodynamic consequences of the stenosis.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Aortic stenosis is a progressive disease and does not have a life threatening cause.
Common Causes
Click here for the complete list of causes.
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.[1]
Boxes in the red signify that an urgent management is needed.
Abbreviations: AVR: Aortic valve replacement; CK-MB: Creatine kinase myocardial type; ECG: Electrocardiogram; NSTEMI: Non ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; TTE: Transthoracic echocardiography
Identify cardinal findings that increase the pretest probability of aortic stenosis ❑ Systolic ejection murmur
❑ Pulsus parvus et tardus (a weak and slow upstroke of the carotid waveform is an excellent indicator of aortic stenosis severity) | |||||||||||||||||||||||||||||||||||||||||||||
Does the patient have any of the following findings require urgent management? ❑ Tachycardia ❑ Hypotension ❑ Severe dyspnea ❑ Loss of consciousness ❑ Chest pain | |||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||
Proceed to the complete diagnostic approach below | |||||||||||||||||||||||||||||||||||||||||||||
The patient has a condition that exacerbates AS | The patient has a decompensated AS causing complications | ||||||||||||||||||||||||||||||||||||||||||||
❑ Suspect if there are palpitations ❑ Order an ECG immediately looking for
| ❑ Suspect if there is loss of consciousness of:
| ❑ Suspect if there are:
| |||||||||||||||||||||||||||||||||||||||||||
❑ Treat the complications of aortic stenosis that lead to decompensation ❑ Order a TTE to evaluate the severity of the aortic stenosis ❑ Do not give nitrates (could cause severe hypotension) ❑ Monitor vital signs continuously | |||||||||||||||||||||||||||||||||||||||||||||
Does the patient improve with medical therapy? | |||||||||||||||||||||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||||||||||||||||||||
❑ Proceed with urgent AVR | |||||||||||||||||||||||||||||||||||||||||||||
Complete Diagnostic Approach
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[1]
Abbreviations: AS: Aortic stenosis; AF: Atrial fibrillation; AVR: Aortic valve replacement; CXR: Chest X-ray; ECG: Electrocardiogram; LBBB: Left bundle branch block; LVH: Left ventricle hypertrophy; TAVR: Transcatheter aortic valve replacement; TTE: Transthoracic echocardiography; VHD: Valvular heart disease
Characterize the symptoms: ❑ Chest pain, angina-type pain (Left untreated, the average survival is 5 years after the onset of angina in the patient with AS)
❑ Syncope (Left untreated, the average survival is 3 years after the onset of syncope in the patient with AS)
| |||||||||||||||||||||||||||||||||||||
Examine the patient: Vitals
❑ Respiratory rate
❑ Pulses
Click on the video below to listen to an aortic stenosis murmur.
{{#ev:youtube|MJg257pyt4I|200}}
| |||||||||||||||||||||||||||||||||||||
Order tests: ❑ TTE (most important evaluation test) (Class I; Level of Evidence: B)
❑ ECG (shows non-specific findings):
❑ Chest X-ray:
| |||||||||||||||||||||||||||||||||||||
Classify aortic stenosis based on the following findings on TTE: ❑ Valve area (cm²) ❑ Transvalvular pressure gradient (mmHg) ❑ Aortic Vmax (m/s) | |||||||||||||||||||||||||||||||||||||
No stenosis ❑ Valve area 2.5-3.5 cm² ❑ No pressure gradient across the valve ❑ Aortic Vmax <2 m/s | Mild stenosis ❑ Valve area 1.5-2.5 cm² ❑ Pressure gradient ≤ 25 mmHg ❑ Aortic Vmax 2.0-2.9 m/s | Moderate stenosis ❑ Valve area 1.0-1.5 cm² ❑ Pressure gradient 25-40 mmHg ❑ Aortic Vmax 3.0-3.9 m/s | Severe stenosis ❑ Valve area ≤ 1.0 cm² ❑ Pressure gradient ≥ 40 mmHg (except for stages D2 and D3, low flow low gradient) ❑ Aortic Vmax ≥ 4 m/s | ||||||||||||||||||||||||||||||||||
Treatment
Indications for Aortic Valve Replacement
Shown below is an algorithm depicting the indications for aortic valve replacement (AVR). If the patient does not meet any of the decision pathways in the algorithm, regular monitoring is recommended and AVR is not indicated.[1]
Abbreviations: AVR: Aortic valve replacement; LVEF: Left ventricular ejection fraction; ΔPmean: mean pressure gradient; Vmax: maximum velocity
Abnormal aortic valve AND Reduction in systolic opening | |||||||||||||||||||||||||||||||||||||||||||||||||||
Severe aortic stenosis: Vmax≥4m/s AND ΔPmean≥40 mmHg | Vmax3-3.9 m/s AND ΔPmean20-39 mmHg | ||||||||||||||||||||||||||||||||||||||||||||||||||
Is the patient symptomatic? | Is the patient symptomatic? | ||||||||||||||||||||||||||||||||||||||||||||||||||
Yes (Stage D1) | No (Stage C) | Yes | No (Stage B) | ||||||||||||||||||||||||||||||||||||||||||||||||
LVEF <50% (Stage C2) | Is LVEF <50%? | The patient is undergoing another cardiac surgery | |||||||||||||||||||||||||||||||||||||||||||||||||
The patient is undergoing another cardiac surgery | Yes | No | |||||||||||||||||||||||||||||||||||||||||||||||||
Vmax≥5m/s AND ΔPmean≥60 mmHg (Very severe stage C1) AND Low surgical risk | Dobutamine stress echocardiography: Aortic valve area ≤1 cm2 AND Vmax≥4 ms (Stage D2) | Aortic valve area ≤1 cm2 AND LVEF ≥50% (Stage D3) | |||||||||||||||||||||||||||||||||||||||||||||||||
Abnormal exercise treadmill test | The symptoms are likely the result of the aortic stenosis | ||||||||||||||||||||||||||||||||||||||||||||||||||
ΔVmax>0.3 m/s/y AND Low surgical risk | |||||||||||||||||||||||||||||||||||||||||||||||||||
AVR (Class I) | AVR (Class IIa) | AVR (Class IIb) | AVR (Class IIa) | AVR (Class IIa) | AVR (Class IIa) | ||||||||||||||||||||||||||||||||||||||||||||||
Choice of Intervention
Shown below is a table summarizing the choice of aortic valve replacement among patients with aortic stenosis based on the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease [1]
Choice of AVR | Indications |
Surgical AVR | - Low or intermediate surgical risk |
Tansthoracic aortic valve replacement (TAVR) | - Prohibitive surgical risk and a predicted post-TAVR survival >12 month (Class I; Level of Evidence: B) |
Evaluation of Surgical and Interventional Cardiac Risk
Shown below is a table to assess the surgical and interventional risk which combines the Society of Thoracic Surgeons (STS) risk estimate, frailty, major organ system dysfunction and procedure-specific impediments.[1]
STC Predicted Risk of Mortality Score[2] | Frailty* | Major organ system compromised without postoperative improvement | Specific procedural impediment** | |
Low risk (Must meet ALL criteria in this row) |
<4% | None | None | None |
Intermediate risk (Must meet ANY criteria in this row) |
4% to 8% | 1 index (mild) | 1 organ system | Possible |
High risk (Must meet ANY criteria in this row) |
>8% | ≥2 indices (moderate to severe) | No more than 2 organ systems | Possible |
Prohibitive risk (Must meet ANY criteria in this row) |
>50% of predicted risk of death or major morbidity at 1 year | >50% of predicted risk of death or major morbidity at 1 year | ≥3 organ systems | Severe |
*Seven frailty indices: Katz Activites of Daily Living (self-sufficient in feeding, bathing, dressing, transferring, toileting, and urinary continence) and self-sufficient in deambulation (no walking aid or assist required or 5-meter walk in <6 s).
**Examples of specific procedural impediment: tracheostomy present, heavily calcified ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall or radiation damage.
Type of Valve and Discharge Anticoagulation Therapy
Abbreviations: AVR: Aortic valve replacement; INR: International normalized ratio; TAVR Tansthoracic aortic valve replacement
Determine: ❑ Age ❑ Contraindications for anticoagulation
| |||||||||||||||||||||||||||||||||
❑ Patients ≤ 60 years old AND ❑ No contraindication for anticoagulation (Class IIa; Level of Evidence: B) | ❑ Patients 60 - 70 years old AND ❑ No contraindication for anticoagulation | ❑ Patients ≥ 70 years old (Class IIa; Level of Evidence: B) OR ❑ Patients at any age AND contraindications for anticoagulation therapy (Class I; Level of Evidence: C) | |||||||||||||||||||||||||||||||
Bioprosthesic OR Mechanical prosthesis (Class IIa; Level of Evidence: B) | |||||||||||||||||||||||||||||||||
Mechanical prosthesis Avoid the use of direct thrombin inhibitors or anti-Xa agents in patients with mechanical prosthesis (Class III; Level of Evidence: B) | Bioprosthesis | ||||||||||||||||||||||||||||||||
Does the patient have risk factors for thromboembolism†? | Surgical AVR OR TAVR | ||||||||||||||||||||||||||||||||
Yes | No | Surgical AVR | |||||||||||||||||||||||||||||||
Administer for long term: ❑ Warfarin to achieve INR of 3.0 (Class I; Level of Evidence: B) AND ❑ Aspirin 75-100 mg/d (Class I; Level of Evidence: A) | Administer for long term: ❑ Warfarin to achieve INR of 2.5 (Class I; Level of Evidence: B) AND ❑ Aspirin 75-100 mg/d (Class I; Level of Evidence: A) | Administer ❑ Warfarin to achieve INR of 2.5 for 3 months (Class IIb; Level of Evidence: B) AND ❑ Aspirin 75-100 mg/d long term (Class IIa; Level of Evidence: B) | Administer:
| ||||||||||||||||||||||||||||||
Do's
- Administer ACE inhibitors to control hypertension among patients with asymptomatic aortic stenosis.[3]
- Perform a transthoracic echocardiography (TTE) after aortic valve replacement to evaluate the valve hemodynamics (Class I; Level of Evidence: B).[1]
- Perform a TTE when clinical symptoms or signs suggest prosthetic valve dysfunction (Class I; Level of Evidence: C).[1]
- Consider exercise testing in asymptomatic patients with aortic stenosis to elicit exercise-induced symptoms and abnormal blood pressure responses (Class IIb; Level of Evidence: B).[1]
- Consider dobutamine stress echocardiography to evaluate patients with low-flow/low-gradient AS and LV dysfunction (Stage D3) (Class IIa; Level of Evidence: B).[1]
- Consider aortic balloon valvotomy as a bridge to surgery in hemodynamically unstable adult patients with aortic stenosis among whom aortic valve replacement cannot be performed because of a high surgical risk or due to the presence of serious comorbid conditions.(Class IIb; Level of Evidence: C).[1]
Don'ts
- Do not perform a stress test in a symptomatic patient with stage D aortic stenosis (Class III; Level of Evidence: B).[1]
- Do not administer statins to prevent hemodynamic progression in patients with mild to moderate calcific aortic valve disease (Class III; Level of Evidence: A).[1]
- Do not perform a transcatheter aortic valve implantation (TAVR) among patients in whom existing comorbidities would preclude the expected benefit from the correction of aortic stenosis (Class III; Level of Evidence: B).[1]
- Do not administer vasodilators to patients with severe aortic stenosis because vasodilators may cause severe hypotension which can precipitate or exacerbate the symptoms of aortic stenosis.[1]
- Do not administer endocarditis prophylaxis among patients with aortic stenosis.[4]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 Nishimura, R. A.; Otto, C. M.; Bonow, R. O.; Carabello, B. A.; Erwin, J. P.; Guyton, R. A.; O'Gara, P. T.; Ruiz, C. E.; Skubas, N. J.; Sorajja, P.; Sundt, T. M.; Thomas, J. D. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000031. ISSN 0009-7322.
- ↑ "Online STS Risk Calculator". Retrieved 7 March 2014.
- ↑ Chambers, J. (2005). "The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors". Heart. 92 (3): 420–423. doi:10.1136/hrt.2005.074112. ISSN 1355-6037.
- ↑ Bonow, RO.; Carabello, BA.; Chatterjee, K.; de Leon, AC.; Faxon, DP.; Freed, MD.; Gaasch, WH.; Lytle, BW.; Nishimura, RA. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter
|month=
ignored (help)